Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on October 23, 2026, solely to submit an Exhibit 99.1 notification regarding unqu | Oct 23, 2026 |
| EVAX | 6-K | bullish | 7/10 | Evaxion reported three-year follow-up data from its Phase 2 trial of personalized cancer vaccine EVX-01 in advanced mela | Oct 23, 2026 |
| LYCA | EFFECT | bullish | 7/10 | Lycia Therapeutics' IPO registration (S-1, File No. 333-299300) became effective on October 22, 2026. The company is now | Oct 23, 2026 |
| PULM | EFFECT | bearish | 5/10 | The SEC declared effective Pulmatrix's S-3 shelf registration (File No. 333-296478) on October 22, 2026, enabling the re | Oct 23, 2026 |
| LNAI | 8-K | bearish | 9/10 | Lunai Bioworks received a Nasdaq delisting determination due to a stockholders' deficit of $(9,024,946), violating the $ | Oct 22, 2026 |
| GILD | INST-CLUSTER | bearish | 4/10 | Five institutional asset managers trimmed or nearly exited their GILD positions in Q3 2026, with aggregate net selling o | Oct 22, 2026 |
| RTSN | 8-K | neutral | 2/10 | Retension Pharmaceuticals appointed Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Office | Oct 22, 2026 |
| NTHI | 8-K | neutral | 3/10 | NeOnc Technologies filed an 8-K reporting three press releases: early clinical improvement in a single pediatric compass | Oct 22, 2026 |
| ENLV | 6-K | neutral | 3/10 | Enlivex Ltd. announced a 1-for-16 reverse share split effective October 27, 2026, approved by shareholders at an Extraor | Oct 22, 2026 |
| ENLV | PRESS-RELEASE | neutral | 3/10 | Enlivex announced a 1-for-16 reverse stock split effective October 27, 2026, to regain compliance with Nasdaq listing re | Oct 22, 2026 |
| IRON | 8-K | bearish | 6/10 | Disc Medicine completed a $450M upsized public offering of 6M shares at $75/share, raising ~$422.4M net proceeds to exte | Oct 22, 2026 |
| JAGX | S-3 | bearish | 5/10 | Jaguar Health filed a new S-3 shelf registration to register up to $75 million of securities, replacing its prior shelf | Oct 22, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk Holdings announced the departure of Chief Business Officer Thomas Lynch, effective October 16, 2026. The compan | Oct 22, 2026 |
| SAFX | 8-K | mixed | 6/10 | XCF Global completed its all-stock business combination with Southern Energy Renewables and DevvStream, creating a verti | Oct 22, 2026 |
| AGIO | 144 | neutral | 2/10 | Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 on October 22, 2026, indicating intent to sell 500 | Oct 22, 2026 |
| SRZN | SC 13D/A | neutral | 4/10 | The Column Group entities filed Amendment No. 7 to their Schedule 13D on Surrozen, Inc., reporting a reduction in aggreg | Oct 22, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma disclosed that its trustee purchased 200,000 existing shares on-market for ~HK$5.74 million (avg ~HK$28 | Oct 22, 2026 |
| PCSA | DEF 14A | neutral | 4/10 | Processa Pharmaceuticals is holding a special meeting on November 30, 2026, to seek stockholder approval for a reverse s | Oct 22, 2026 |
| LFVN | SC 13G/A | neutral | 3/10 | Capital Management Corp /VA filed an amended Schedule 13G on 10/22/2026, reporting a 18.3% passive stake in Lifevantage | Oct 22, 2026 |
| AYTU | DEF 14A | neutral | 4/10 | Aytu BioPharma filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval for five p | Oct 22, 2026 |
| SHPH | 8-K | bearish | 6/10 | Shuttle Pharmaceuticals dismissed its auditor, Forvis Mazars, effective after the Q3 2026 10-Q filing. The dismissal fol | Oct 22, 2026 |
| KNSA | 8-K | neutral | 2/10 | Kiniksa appointed Ross Moat as President and COO, effective immediately, with a base salary increase to $700,000 and tar | Oct 22, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a 1-for-10 reverse stock split effective October 26, 2026, to regain compliance with Nasdaq' | Oct 22, 2026 |
| SABS | 25-NSE | neutral | 2/10 | Nasdaq filed a Form 25-NSE to remove from listing and deregister SAB Biotherapeutics' warrants expiring October 22, 2026 | Oct 22, 2026 |
| AARD | 8-K | bullish | 7/10 | Aardvark Therapeutics announced that the FDA has lifted the clinical hold on its IND for ARD-101 for hyperphagia in Prad | Oct 22, 2026 |
| MGNX | 144 | neutral | 2/10 | Former director Karen Ferrante filed a Form 144 indicating intent to sell 22,000 shares of MacroGenics common stock. The | Oct 22, 2026 |
| AZTR | 8-K | neutral | 3/10 | Azitra, Inc. filed a certificate of amendment to effect a 1-for-10 reverse stock split, effective October 26, 2026. The | Oct 22, 2026 |
| CTNM | SC 13G | neutral | 3/10 | Trails Edge Capital Partners, LP and related entities filed a Schedule 13G disclosing a 5.1% passive stake in Contineum | Oct 22, 2026 |
| KPTI | 8-K | bearish | 6/10 | Karyopharm Therapeutics filed an 8-K extending its forbearance period under a Forbearance Agreement and Limited Waiver t | Oct 22, 2026 |
| KRSA | 144 | neutral | 2/10 | Director Michael J. Higgins filed a Form 144 notice of intent to sell 1,107 shares of Korsana Biosciences common stock, | Oct 22, 2026 |